Navigating FDA and ICH Guidelines: Analytical Testing Validation for Tobacco Products.
![](https://www.broughton-group.com/hs-fs/hubfs/Picture1fda.jpg?width=696&height=400&name=Picture1fda.jpg)
Staying on top of regulatory changes, new technical innovations, and industry-disrupting competitors has never been harder. With so much information available, how do you ensure you have the insight you need to drive your business forward and seize opportunities before the competition?
Our regulatory and scientific experts are here to help you stay up to speed with new trends and research. Let them share their expertise and insight so you can focus on building your business.
Browse our resource library to get more insight into the latest industry trends and a better understanding of the right regulatory framework to choose for your innovation or new product. Learn how our scientific and regulatory experts can help create competitive advantage and new business opportunities through their insight and expertise.
Filter
Stability studies are essential in ensuring drug products remain safe, effective, and high-quality throughout their shelf life. While bundled services often include stability testing, hidden costs and limitations can create challenges.
Click to downloadBroughton is a leading global contract research organisation specialising in tobacco harm reduction, medicinal cannabis, cannabinoids, and pharmaceuticals, we can help bring category innovators life-enhancing products to market.
Click to downloadWith over 60,000 liters of in-house ICH stability storage capacity, supported by a team of highly qualified scientists and GMP-accredited laboratory testing facilities, we have approximately 250 live studies in progress and offer a full range of stability services to help bring your product to market or ensure its ongoing compliance requirements.
Click to download
For category innovators thorough stability studies are vital for successful drug development and regulatory approval.
Click to downloadThe MHRA is now a stand-alone body issuing national authorisations only. This infographic outlines the routes to a Pharmaceutical Marketing Authorisation in the UK.
Click to downloadThe evaluation of extractables and leachables (E&L) is an essential component of the pharmaceutical development process.
Click to downloadOur team of in-house toxicologists reviews and evaluates toxicological data on a wide range of chemicals to produce independent expert opinions on risk assessment. We then advise on the strategies to mitigate or reduce those risks to protect corporate reputation and public health.
Click to downloadDeveloping and commercializing new inhaled drug products, requires huge energy and deep scientific understanding. This level of resource and subject matter expertise can be difficult to maintain inside your business, and that is where we can help.
Click to downloadOur product development and regulatory experts can help you meet expectations at key milestones in your product development project to better inform decision making and investment choices.
Click to downloadWe believe that the sectors we work within expect a continually improving service where we constantly strive to improve processes and Quality.
Click to downloadToxHQ by Broughton offers automated, data-driven risk assessments and delivers fast, high-quality toxicological evaluations, so you can launch safer products with confidence.
Click to downloadIn this whitepaper, we discuss the stability studies that may be performed during pharmaceutical development and in support of a regulatory dossier to support the licensing of a medicinal drug product.
Click to downloadIn this whitepaper, we discuss the stability studies that may be performed during pharmaceutical development and in support of a regulatory dossier to support the licensing of a medicinal drug product.
Click to downloadExtractables and leachables (E&L) risk assessments are valuable processes that can identify and highlight the risks of potential leachables from both the container closure system and the manufacturing processes. The risk assessments also include the level of risk that leachables might present to user safety and product quality. Download this Whitepaper to learn more.
Click to downloadSince their introduction in 1956, pressurised metered dose inhalers (pMDIs) have become the dominant treatment choice for patients suffering from common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). However, unbeknown to most patients and many doctors, pMDIs account for 3.9% of NHS’s annual carbon emissions. 1Here we will discuss how formulation changes might be the answer to the pMDI-related sustainability problem.
Click to downloadThe adaptation of e-cigarettes as drug delivery devices holds great potential for inhalation therapy. So, can we apply the advances made in nicotine delivery to other active substances?
Click to download3 minute read
Navigating FDA and ICH Guidelines: Analytical Testing Validation for Tobacco Products.
Helping you and your business stay ahead of the competition with regular updates on the latest regulatory changes and industry news.